Myelinopathy
Conditions
Brief summary
The cases were screened according to the inclusion criteria, and after the patients signed the informed consent, the clinical data were collected, the imaging data were evaluated, and blood samples were taken for follow-up measurements. In the early morning of the second day after the patient was enrolled, 5mL of peripheral venous blood was drawn and sent to the neurology laboratory of our hospital for separation, and the detection of plasma metabolomics markers was performed.
Detailed description
In the early morning of the second day after the patient was enrolled, 5mL of peripheral venous blood was drawn and sent to the neurology laboratory of our hospital for separation, and the detection of plasma metabolomics markers was performed.Inluding CRP，Complete blood count，Liver and kidney function indicators，et.
Interventions
DIAGNOSTIC_TESTwhite matter lesion
According to the results of magnetic resonance, they were divided into white matter degeneration group and non-white matter degeneration group
Sponsors
Nanjing First Hospital, Nanjing Medical University
Study design
Observational model
COHORT
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
45 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
： 1. Be older than 45 years old; 2. Patients admitted to the Department of Neurology due to headache, vertigo, anxiety, etc.; 3. There were no symptoms of neurological deficit on physical examination; 4. Able to cooperate with the improvement of brain MRI examination; 5. Sign the informed consent form.
Exclusion criteria
1. History of stroke, traumatic brain injury, intracranial tumor, central nervous system infection, active malignant tumor, thyroid disease, autoimmune disease, active or chronic inflammatory disease, severe liver and kidney impairment, etc.; 2. accompanied by neurological deficit symptoms; 3. refusal to participate in the study; 4. Other conditions judged by the investigator to be unsuitable for enrollment.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| myelinopathy | 2024.06.01-2027.06.01 | The degree of damage to the white matter of the brain is judged based on the magnetic resonance Fazekas score(1-3), with the higher scores indicating the damage more severe. |
Countries
China
Outcome results
None listed